N
AXSM icon

Nuveen’s Axsome Therapeutics AXSM Stock Holding History

Nuveen’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.7M Sell
335,737
-13,472
-4% -$2.33M 0.02% 589
2025
Q4 		$63.8M Buy
349,209
+50,868
+17% +$7.1M 0.02% 538
2025
Q3 		$36.2M Buy
298,341
+15,370
+5% +$1.73M 0.01% 787
2025
Q2 		$29.5M Sell
282,971
-130,170
-32% -$13.8M 0.01% 867
2025
Q1 		$48.2M Buy
413,141
+191,939
+87% +$21.9M 0.01% 634
2024
Q4 		$18.7M Buy
221,202
+119,780
+118% +$11M 0.01% 1228
2024
Q3 		$9.11M Sell
101,422
-1,223
-1% -$107K ﹤0.01% 1664
2024
Q2 		$8.26M Sell
102,645
-142,882
-58% -$10.6M ﹤0.01% 1699
2024
Q1 		$19.6M Buy
245,527
+10,881
+5% +$913K 0.01% 1195
2023
Q4 		$18.7M Buy
234,646
+18,089
+8% +$1.21M 0.01% 1206
2023
Q3 		$15.1M Buy
216,557
+115,342
+114% +$8.62M 0.01% 1217
2023
Q2 		$7.27M Sell
101,215
-13,307
-12% -$982K ﹤0.01% 1693
2023
Q1 		$7.06M Sell
114,522
-7,423
-6% -$488K ﹤0.01% 1692
2022
Q4 		$9.41M Sell
121,945
-571,579
-82% -$34.2M ﹤0.01% 1535
2022
Q3 		$30.9M Sell
693,524
-77,473
-10% -$3.87M 0.01% 746
2022
Q2 		$29.5M Buy
770,997
+348,317
+82% +$11M 0.01% 792
2022
Q1 		$14.1M Sell
422,680
-71,526
-14% -$2.22M ﹤0.01% 1418
2021
Q4 		$18.7M Buy
494,206
+2,949
+0.6% +$109K 0.01% 1271
2021
Q3 		$14.6M Sell
491,257
-167,077
-25% -$6.51M ﹤0.01% 1498
2021
Q2 		$44.4M Buy
658,334
+159,584
+32% +$9.58M 0.01% 814
2021
Q1 		$28.2M Sell
498,750
-8,433
-2% -$593K 0.01% 1065
2020
Q4 		$41.3M Sell
507,183
-24,372
-5% -$1.82M 0.01% 805
2020
Q3 		$37.9M Buy
531,555
+314,466
+145% +$24.5M 0.01% 692
2020
Q2 		$17.9M Buy
217,089
+35,913
+20% +$2.76M 0.01% 1119
2020
Q1 		$10.7M Buy
181,176
+80,000
+79% +$6.52M 0.01% 1254
2019
Q4 		$10.5M Sell
101,176
-2,383
-2% -$96.2K ﹤0.01% 1566
2019
Q3 		$2.1M Buy
103,559
+5,837
+6% +$150K ﹤0.01% 2372
2019
Q2 		$2.52M Buy
+97,722
New +$1.96M ﹤0.01% 2322

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's AXSM Position: Q1 2026 in Review

Nuveen reduced its Axsome Therapeutics (AXSM) stake by 3.9% in Q1 2026, selling an estimated $2.33M and leaving 335,737 shares worth $56.7M. The position accounts for 0.02% of the portfolio, ranked #589.

Nuveen first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $63.8M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Nuveen held 335,737 shares of Axsome Therapeutics worth $56.7M as of Q1 2026.
  • Nuveen sold 13,472 Axsome Therapeutics shares in Q1 2026, an estimated $2.33M.
  • Axsome Therapeutics made up 0.02% of Nuveen's portfolio in Q1 2026, its #589 holding.
  • Nuveen first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Axsome Therapeutics position peaked at $63.8M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.